Please use this identifier to cite or link to this item: https://ktisis.cut.ac.cy/handle/10488/22758
Title: A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD)
Authors: Charalambous, Andreas 
Tsitsi, Theologia 
Astras, George 
Paikousis, Lefkios 
Filippou, Elena 
Major Field of Science: Medical and Health Sciences
Field Category: Clinical Medicine
Keywords: Capecitabine;Hand-foot syndrome;Palmar-plantar erythrodysesthesia;Pegylated liposomal doxorubicin;Quality of life;Symptom management
Issue Date: Feb-2021
Source: European Journal of Oncology Nursing, 2021, vol. 50, articl. no. 101866
Volume: 50
Journal: European Journal of Oncology Nursing 
Abstract: Purpose: Palmar-Plantar Erythrodysesthesia (PPE) is a dose-limiting adverse event that commonly occurs with capecitabine and Pegylated Liposomal Doxorubicin-PLD treatment. The study aimed to test the effectiveness of a Pyridoxine (B6) treatment protocol in the management of PPE in patients receiving treatment with capecitabine or pegylated liposomal doxorubicin. Methods: This was a pilot randomized double-blind, placebo-controlled study. Patients receiving capecitabine or pegylated liposomal doxorubicin with PPE grade 1 or above were randomly allocated to receive pyridoxine or placebo. The PPE grade, Quality of Life-QoL, Pain and patients’ activities of daily living were assessed. Results: Thirty patients were assigned in the Control and 24 in the Intervention group. No statistically significant difference was found in the PPE grade between baseline and week 6 in the 2 groups (p = 0.263). The control group exhibited worst PPE-associated QoL and higher PAIN levels between baseline and week 6. Respectively, the intervention group showed improved PPE-associated QoL and lower PAIN levels. At week 6, the ECOG status in the Intervention group was improved compared to the control (p = 0.018). Patients in the Intervention group experienced better Global Health Status (p = 0.012), Physical (p = 0.003), Emotional (p = 0.008), and Social function (p < 0.001), lower Fatigue (p = 0.001) and Pain (p = 0.006) compared to Control. Conclusion: Topical pyridoxine was not shown to have an effect on the treatment of PPE. However, results demonstrated its effectiveness on health related QoL, QoL-associated with PPE and pain levels. Due to the high attrition rate further validation of these results in a larger population is warranted. ClinicalTrials.gov identifier: NCT02625415.
URI: https://ktisis.cut.ac.cy/handle/10488/22758
ISSN: 1462-3889
DOI: 10.1016/j.ejon.2020.101866
Rights: © Elsevier
Attribution-NonCommercial-NoDerivatives 4.0 International
Type: Article
Affiliation : Cyprus University of Technology 
University of Turku 
American Medical Center 
Improvast 
Appears in Collections:Άρθρα/Articles

CORE Recommender
Show full item record

Page view(s)

39
Last Week
0
Last month
13
checked on Sep 22, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons